Is Australia positioned to take advantage of biosimilars?

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Australia currently has a small generic and biosimilar medicine industry despite having a good track record in biomedical research and a sound reputation in producing high quality but small volume biological pharmaceuticals. In recent times, Australia has made incremental changes to its regulation of biosimilars – in patent registration, in the use of commercial confidential information, and in remuneration. These improvements, together with Australia’s geographical proximity and strong trade relationship with the Asian biocluster, have positioned Australia to take advantage of potential public cost savings from the increased use of biosimilars.
Original languageEnglish
Pages (from-to)184-187
Number of pages4
JournalGenerics and Biosimilars Initiative Journal
Volume3
Issue number4
Publication statusPublished - 2014

Keywords

  • Australia
  • biosimilars
  • confidential business information
  • patents

Fingerprint

Dive into the research topics of 'Is Australia positioned to take advantage of biosimilars?'. Together they form a unique fingerprint.

Cite this